tetano
Editor, Senior Moderator
Infect Drug Resist. 2017 Jul 20;10:215-226. doi: 10.2147/IDR.S138317. eCollection 2017.
[h=1]Assessing the oseltamivir-induced resistance risk and implications for influenza infection control strategies.[/h] Hsieh NH[SUP]1[/SUP], Lin YJ[SUP]2[/SUP], Yang YF[SUP]2[/SUP], Liao CM[SUP]2[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] [h=4]BACKGROUND:[/h] Oseltamivir-resistant mutants with higher drug resistance rates and low trans-mission fitness costs have not accounted for influenza (sub)type viruses. Predicting the impacts of neuraminidase inhibitor therapy on infection rates and transmission of drug-resistant viral strains requires further investigation.
[h=4]OBJECTIVES:[/h] The purpose of this study was to assess the potential risk of oseltamivir-induced resistance for influenza A (H1N1) and A (H3N2) viruses.
[h=4]MATERIALS AND METHODS:[/h] An immune-response-based virus dynamic model was used to best fit the oseltamivir-resistant A (H1N1) and A (H3N2) infection data. A probabilistic risk assessment model was developed by incorporating branching process-derived probability distribution of resistance to estimate oseltamivir-induced resistance risk.
[h=4]RESULTS:[/h] Mutation rate and sensitive strain number were key determinants in assessing resistance risk. By increasing immune response, antiviral efficacy, and fitness cost, the spread of resistant strains for A (H1N1) and A (H3N2) were greatly decreased. Probability of resistance depends most strongly on the sensitive strain number described by a Poisson model. Risk of oseltamivir-induced resistance increased with increasing the mutation rate for A (H1N1) only. The ≥50% of resistance risk induced by A (H1N1) and A (H3N2) sensitive infected cells were 0.4 (95% CI: 0.28-0.43) and 0.95 (95% CI 0.93-0.99) at a mutation rate of 10[SUP]-6[/SUP], respectively. Antiviral drugs must be administrated within 1-1.5 days for A (H1N1) and 2-2.5 days for A (H3N2) virus infections to limit viral production.
[h=4]CONCLUSION:[/h] Probabilistic risk assessment of antiviral drug-induced resistance is crucial in the decision-making process for preventing influenza virus infections.
[h=4]KEYWORDS:[/h] influenza; oseltamivir; probabilistic risk assessment; resistance risk
PMID: 28790857 PMCID: PMC5529381 DOI: 10.2147/IDR.S138317
Free PMC Article
[h=1]Assessing the oseltamivir-induced resistance risk and implications for influenza infection control strategies.[/h] Hsieh NH[SUP]1[/SUP], Lin YJ[SUP]2[/SUP], Yang YF[SUP]2[/SUP], Liao CM[SUP]2[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] [h=4]BACKGROUND:[/h] Oseltamivir-resistant mutants with higher drug resistance rates and low trans-mission fitness costs have not accounted for influenza (sub)type viruses. Predicting the impacts of neuraminidase inhibitor therapy on infection rates and transmission of drug-resistant viral strains requires further investigation.
[h=4]OBJECTIVES:[/h] The purpose of this study was to assess the potential risk of oseltamivir-induced resistance for influenza A (H1N1) and A (H3N2) viruses.
[h=4]MATERIALS AND METHODS:[/h] An immune-response-based virus dynamic model was used to best fit the oseltamivir-resistant A (H1N1) and A (H3N2) infection data. A probabilistic risk assessment model was developed by incorporating branching process-derived probability distribution of resistance to estimate oseltamivir-induced resistance risk.
[h=4]RESULTS:[/h] Mutation rate and sensitive strain number were key determinants in assessing resistance risk. By increasing immune response, antiviral efficacy, and fitness cost, the spread of resistant strains for A (H1N1) and A (H3N2) were greatly decreased. Probability of resistance depends most strongly on the sensitive strain number described by a Poisson model. Risk of oseltamivir-induced resistance increased with increasing the mutation rate for A (H1N1) only. The ≥50% of resistance risk induced by A (H1N1) and A (H3N2) sensitive infected cells were 0.4 (95% CI: 0.28-0.43) and 0.95 (95% CI 0.93-0.99) at a mutation rate of 10[SUP]-6[/SUP], respectively. Antiviral drugs must be administrated within 1-1.5 days for A (H1N1) and 2-2.5 days for A (H3N2) virus infections to limit viral production.
[h=4]CONCLUSION:[/h] Probabilistic risk assessment of antiviral drug-induced resistance is crucial in the decision-making process for preventing influenza virus infections.
[h=4]KEYWORDS:[/h] influenza; oseltamivir; probabilistic risk assessment; resistance risk
PMID: 28790857 PMCID: PMC5529381 DOI: 10.2147/IDR.S138317
Free PMC Article